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H I G H L I G H T S
• Neuronal injury is a major component of HAND pathology.• Endocannabinoid drugs show promise as a treatment for neurodegenerative disease.• Assessment of cannabinoid based interventions in neuroAIDS is limited.• FAAH inhibition blocks Tat induced neuronal dysfunction via cannabinoid receptors.
A R T I C L E I N F O
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A B S T R A C T
The HIV-1 transactivator of transcription (Tat) is a neurotoxin involved in the pathogenesis of HIV-1 associated
neurocognitive disorders (HAND). The neurotoxic effects of Tat are mediated directly via AMPA/NMDA receptor
activity and indirectly through neuroinflammatory signaling in glia. Emerging strategies in the development of
neuroprotective agents involve the modulation of the endocannabinoid system. A major endocannabinoid,
anandamide (N-arachidonoylethanolamine, AEA), is metabolized by fatty acid amide hydrolase (FAAH). Here
we demonstrate using a murine prefrontal cortex primary culture model that the inhibition of FAAH, using
PF3845, attenuates Tat-mediated increases in intracellular calcium, neuronal death, and dendritic degeneration
via cannabinoid receptors (CB1R and CB2R). Live cell imaging was used to assess Tat-mediated increases in
[Ca2+]i, which was significantly reduced by PF3845. A time-lapse assay revealed that Tat potentiates cell death
while PF3845 blocks this effect. Additionally PF3845 blocked the Tat-mediated increase in activated caspase-3
(apoptotic marker) positive neurons. Dendritic degeneration was characterized by analyzing stained dendritic
processes using Imaris and Tat was found to significantly decrease the size of processes while PF3845 inhibited
this effect. Incubation with CB1R and CB2R antagonists (SR141716A and AM630) revealed that PF3845-medi-
ated calcium effects were dependent on CB1R, while reduced neuronal death and degeneration was CB2R-
mediated. PF3845 application led to increased levels of AEA, suggesting the observed effects are likely a result of
increased endocannabinoid signaling at CB1R/CB2R. Our findings suggest that modulation of the endogenous
cannabinoid system through inhibition of FAAH may be beneficial in treatment of HAND.
1. Introduction
Combination antiretroviral therapy (cART) has greatly improved
the life expectancy of patients infected with human immunodeficiency
virus 1 (HIV-1), however many still exhibit mild neurocognitive deficits
referred to as HIV-1 associated neurocognitive disorders (HAND)
(Sacktor et al., 2002; Gannon et al., 2011; Heaton et al., 2011). Severity
of HAND symptoms strongly correlates with synaptodendritic dama-
gesuch as dendritic simplification, axonal disruption, and synaptic loss
(Masliah et al., 1997; Ellis et al., 2007). The HIV-1 transactivator of
transcription (Tat) protein, a neurotoxin that likely plays a major role in
the pathogenesis of HAND (Rappaport et al., 1999; King et al., 2006;
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Rao et al., 2014; Carroll and Brew, 2017), directly disrupts healthy
neuronal function by dysregulating the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid/N-methyl-d-aspartate (AMPA/NMDA) receptor
system leading to increased intracellular sodium ([Na+]i) and calcium
([Ca2+]i) causing mitochondrial instability, enhanced cellular excit-
ability, and swelling and/or loss of functional dendritic structures
(Cheng et al., 1998; Haughey et al., 2001; Prendergast et al., 2002;
Behnisch et al., 2004; Longordo et al., 2006; Brailoiu et al., 2008b;
Zucchini et al., 2013; Bertrand et al., 2014; Fitting et al., 2014).
Moreover, Tat promotes neuroinflammatory signaling (Nath et al.,
1999; Sheng et al., 2000; Hahn et al., 2010; Zou et al., 2011; Jin et al.,
2012), which may be a major component of HAND pathogenesis
(Mattson et al., 2005; Gannon et al., 2011; Harezlak et al., 2011). The
persistence of HAND in the era of cART provokes questions about the
causes and treatment of HIV-1-related brain disorders and whether
cognitive deficits are reversible (Ellis et al., 2007). Endogenous can-
nabinoid ligands N-arachidonoylethanolamine (anandamide/AEA) and
2-arachidonoylglycerol (2-AG) have neuroprotective properties that
likely play a role in several neurological disorders, including Parkin-
son's and Alzheimer's diseases (Scotter et al., 2010; Pertwee, 2014).
AEA and 2-AG primarily target cannabinoid type 1 receptors (CB1Rs)
and cannabinoid type 2 receptors (CB2Rs) and are preferentially de-
graded by fatty acid amide hydrolase (FAAH) and monoacylglycerol
lipase (MAGL), respectively. Neuronal CB1R activation offers neuro-
protection by limiting the synaptic release of glutamate (Marsicano
et al., 2003; Chevaleyre et al., 2006; Rossi et al., 2011; Chiarlone et al.,
2014) and downregulating NMDA receptor activity (Derkinderen et al.,
2003; Marsicano et al., 2003; Liu et al., 2009; Li et al., 2010; Hampson
et al., 2011; Sanchez-Blazquez et al., 2014). Psychoactive side effects
including sensorimotor, affective, and cognitive disturbances limit the
therapeutic utility of CB1R agonists (Di Marzo, 2008). Further, direct
application of AEA and 2-AG have poor clinical viability because their
rapid degradation. Despite the neuroprotective and anti-inflammatory
potential of endogenous cannabinoid hydrolytic enzyme inhibitors,
they have not been evaluated in models of the neuro-acquired immune
deficiency syndrome (neuroAIDS). Strong preclinical evidence shows
that selective inhibitors of FAAH and MAGL ameliorate neurodegen-
erative disease processes in a variety of different animal models
(Naidoo et al., 2011; Pertwee, 2014). Hydrolytic enzyme inhibitors,
such as the FAAH inhibitor PF3845, show high selectivity and potency
with minimal side effects (Ahn et al., 2009; Booker et al., 2012;
Niphakis et al., 2013). Specifically, PF3845 increases neuronal survival,
and elicits anti-nociceptive and anti-inflammatory effects in mice
without cannabimimetic side effects (Booker et al., 2012; Tchantchou
et al., 2014).
The goals of this study were to test whether PF3845 produces
neuroprotective effects in murine prefrontal cortex (PFC)-derived neu-
ronal cultures challenged with neurotoxic concentrations of Tat, and to
identify specific CBRs and potential mechanisms involved in neuro-
protection. By conducting live cell [Ca2+]i imaging studies, time-lapse
cell survival assays, and immunocytochemistry it was demonstrated
that challenging cultured PFC neurons with Tat significantly increases
neuronal [Ca2+]i levels, decreases neuronal survival, and induces loss
of dendrite structure, while preincubating cells with PF3845 amelio-
rates these conditions via CB1R and CB2R-related mechanisms.
2. Material and methods
2.1. Experimental design and statistical analyses
The design of each experiment is detailed in methods provided for
each experiment, including the between-subjects factors and a full de-
scription of critical variables required for independent replication.
2.2. Treatments
Neurons were treated with HIV-1 Tat1–86 (10–500 nM;
ImmunoDiagnostics; clade 267 B), PF3845 (10–100 nM, Dr. Benjamin
Cravatt), CB1R antagonist SR141716A (SR1, 50 nM, Tocris, Ellisville,
MO) and the CB2R antagonist AM630 (50 nM, Tocris, Ellisville, MO).
Concentrations of PF3845 were chosen based on preliminary experi-
ments (data not shown) and previous studies that assessed the activities
of these drugs in vitro (Ahn et al., 2009; Niphakis et al., 2013). Tat
concentrations in the 10–500 nM range were selected as these con-
centrations recapitulate the cellular deficits found in individuals with
HIV-1 mediated pathology (Kruman et al., 1998; El-Hage et al., 2008,
2011; Perry et al., 2010). For all experiments PF3845 was added 30min
prior to experiment start. Tat was added for calcium imaging 1min
after the experiment started, and for neuronal survival and dendrite
morphology assessments at the beginning of experimental studies. In
order to determine the contribution of CB1R and/or CB2R activity to
observed neuroprotective effects, cultures were incubated with SR1 or
AM630 30min prior to PF3845 treatment and were present throughout
the duration of the experiment. Antagonist drug concentrations were
chosen to maximally block treatments based on preliminary explorative
assessments conducted prior to the main experiments.
2.3. Primary neuronal cultures
All experiments were approved by the University of North Carolina
at Chapel Hill and conducted in accordance with the NIH Guide for the
Care and Use of Laboratory Animals. Primary neuronal cultures were
derived from dissociated PFC of embryonic day 15–16 C57BL/6J mice
as previously described (Xu et al., 2017). Collected tissue was minced
and incubated (30min, 37 °C) with trypsin (2.5mg/mL) and DNase
(0.015mg/mL) in neurobasal medium (Invitrogen) supplemented with
B27 (Invitrogen), L-glutamine (0.5mM; Invitrogen), glutamate (25mM;
Sigma-Aldrich) and an antibiotic mixture (Invitrogen). Tissues were
triturated, filtered twice through 70 μm pore nylon mesh and then
plated on MatTek 35mm glass bottom dishes (1×105 cells per dish, for
calcium imaging), on coverslips (2× 105 cells per coverslip, for im-
munocytochemistry), and on 12-well plates (2× 105 cells per well, for
time-lapse survival assays and 3× 105 cells per well, for mass spec-
trometry). All dishes and plates were coated with poly-L-lysine (Sigma-
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Aldrich) one week before use. Cultures were maintained in neurobasal
medium supplemented with B27 (Invitrogen), 0.5 mM L-glutamine,
0.025mM glutamate at 37 °C in a humidified atmosphere containing
5% CO2. All experiments were performed on neuronal cultures at 7–11
days in vitro (DIV) ensuring that dendritic/axonal structures were es-
tablished and cells expressed a full complement of CBR proteins.
2.4. Immunocytochemistry
PFC neuronal cultures were fixed in 4% paraformaldehyde for
10min, and then incubated in blocking buffer (1% normal goat serum,
4% bovine serum albumin in 1x phosphate buffer saline (PBS)) for
1 h at room temperature. Neuronal cultures were then incubated with
primary antibodies against MAP2ab (mouse, Millipore, MAB378,
1:500), and CB1R-NH (raised to amino acids 1–77 of the N-terminus;
rabbit, 1:500 (Tsou et al., 1998);), or glial fibrillary acidic protein
(GFAP; rabbit, Millipore, AB5804, 1:500), diluted in blocking buffer,
overnight at 4 °C. For detecting neurons that undergo apoptosis, cul-
tures were incubated with antibodies against mouse/human active
caspase-3 (rabbit, R&D Systems, AF835-SP, 1:2000) and NeuN (mouse,
Millipore, MAB377, 1:100). Primary antibodies were detected using
appropriate secondary antibodies conjugated to either goat-anti-mouse
Alexa 488 (Molecular Probes, O-6380, 1:1000) or goat-anti-rabbit Alexa
594 (Molecular Probes, A11012, 1:500). Secondary antibodies were
diluted in blocking buffer and applied to the coverslips for 1 h at room
temperature. Neurons were then washed thoroughly with 1x PBS,
counterstained with Hoechst 33342 for 3min and mounted using Pro-
Long Gold (Molecular Probes, P36930). Immunofluorescent images
were acquired using either a Zeiss LSM 700 laser scanning confocal
microscope equipped with a 63× oil immersion objective (Zeiss,
Thornwood, NY) or Zeiss Axio Observer Z.1 inverted microscope
equipped with a 40× oil immersion objective. The percent astrocytes
composition of neuronal cultures was calculated by dividing the
number of GFAP-positive cells by the total number of MAP2ab- and
GFAP-positive cells visualized from 10 to 20 randomly collected
images. At least three independent experiments were run for each
treatment group per time point (DIV 7 & DIV 11). It should be noted
that microglial cells that stained positive for Iba1 are a negligible
component of our PFC neuronal cultures making up less than 0.1% of
observed cells (data not shown). Z-stacks for Imaris analysis were col-
lected using ZEN 2010 blue Edition software (Zeiss, Inc.) and single
images were generated using the orthogonal projection function. Adobe
Photoshop CS6 Extended 13.0 software (Adobe Systems, Inc.; San Jose,
CA) was used to edit the images.
2.5. Calcium imaging
Live cell imaging was conducted on living PFC neurons in culture
using a Zeiss Axio Observer Z.1 inverted microscope (20× objective)
with an automated, computer-controlled stage encoder with environ-
mental control (37 °C, 95% humidity, 5% CO2). The cell permeant
acetoxymethyl (AM) ester-linked [Ca2+]i indicator fura-2AM
(Kd=145 nM; 2.5 μM, Molecular Probes) was used for measuring
[Ca2+]i and diluted in Hank's balanced salt solution (HBSS with Ca2+,
Invitrogen) with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(10mM, Invitrogen) according to manufacturer's instructions. Neurons
were imaged for a 30min period. Using ZEN 2010 blue Edition soft-
ware, images were acquired with a MRm digital camera (Zeiss) at a
frame rate of 0.2 Hz during the first 5min, 0.033Hz from 5min to
10min, and 0.0166Hz from 10 to 30min. Relative fluorescence ratio
images were acquired at 340/380 nm excitation and 510 nm emission
wavelengths. Conversion to [Ca2+]i was calculated according to an
equation described previously (Grynkiewicz et al., 1985). Regions of
interest (ROIs) were manually assigned to neuronal somata. Due to the
heterogeneity among neurons, the mean ± SEM values for changes in
[Ca2+]i were computed comparing individual neurons before and at
specific intervals during treatment using a repeated-measure analysis of
variance (ANOVA). Quantitative analyses of [Ca2+]i levels in neuronal
somata were performed on 12–15 randomly selected neurons per
treatment per experiment. At least three independent experiments were
run for each treatment group.
2.6. Dendrite morphology and Imaris reconstruction
To assess changes in dendritic length (μm), dendritic volume (μm3),
and number of process filaments of neurons, PFC cultures were exposed
to Tat 100 nM for 24 h before being fixed and stained against MAP2ab
(see above). 20–30 neurons were imaged per condition using the Zeiss
LSM 700 confocal microscope. Z-stacks were reconstructed as 3D
images using Imaris software (South Windsor, CT). Dendrites were
drawn using the autoloop function starting at the cell surface and
ending at the terminus of each process. Dendrite volume was de-
termined using the built-in dendrite volume reconstruction algorithm.
All process length, volume, and filament values were calculated by
Imaris and exported for statistical analysis. At least three independent
experiments were run for each treatment group.
2.7. Neuronal survival
PFC neuronal survival was assessed over a 72 h time period using a
Zeiss Axio Observer Z.1 inverted microscope with an automated,
computer-controlled stage encoder with environmental control (37 °C,
95% humidity, 5% CO2). Time-lapse studies were conducted as pre-
viously described (Zou et al., 2011; Xu et al., 2017). PFC neurons were
grown in 12-well plates and 6 non-overlapping fields were selected per
well. Individual neurons were then randomly selected from each field
and changes in their morphology were assessed over time. Time-lapse
images were recorded at 1 h intervals for 72 h using an automated,
computer-controlled stage encoder running Zen 2011 software (Zeiss,
Inc.). Neuronal death was assessed using rigorous morphological cri-
teria, including neurite disintegration, loss of phase brightness and
fragmentation of the cell body. At least three independent experiments
were run for each treatment.
To verify the extent of cell death assessed by the time-lapse survival
studies, activated caspase-3 staining was used to detect apoptotic cells
in our PFC cultures. Neurons stained with anti-NeuN and anti-activated
caspase-3 were imaged using the Zeiss Axio Observer Z.1 microscope,
and the number of activated caspase-3 positive neurons was compared
to the total number of NeuN positive neurons to determine the per-
centage of neurons undergoing apoptotic cell death. 10–15 images were
randomly collected for each experimental condition from three in-
dependent experiments. Results are shown as the fold increase of cas-
pase-3 positive neurons in each condition (DIV 11) compared to the
control baseline condition (DIV 8).
2.8. Lipid extraction and mass spectrometry analysis
Cells were dissociated and centrifuged at 5000 g for 10min at 4 °C.
Cells were stored at −80 °C until analysis. A seven point calibration
curve ranged from 0.028 pmol to 2.8 pmol for AEA, 0.033 pmol to
3.3 pmols for palmitoylethanolamide (PEA), and 0.031 pmol–3.1 pmol
for oleoylethanolamine (OEA). Negative and blank controls were pre-
pared. ISTDs (10 μL of ethanol containing of each the following
0.28 pmol AEA-d8, 0.33 pmol PEA-d4, and 0.31 pmol OEA-d4) was
added to each calibrator, control and sample except the blank control.
Samples were then homogenized in 100 μL of ethanol and then 900 μL
of water was added. Each calibrator, control, and sample was then
extracted using a UCT Clean Up® C18 sold phase extraction column
(UCT, Inc., Bristol, PA). The columns were conditioned with 3mL of
methanol followed by 3mL of deionized water. The samples were
added to the columns and aspirated followed by 2mL of deionized
water. Lipids were then eluted with 2mL of methanol. The extracts
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were evaporated under nitrogen and reconstituted in 50 μL of mobile
phase and placed in auto-sampler vial for Ultrahigh Performance Liquid
Chromatography (UPLC) tandem mass spectrometry (MS/MS) analysis.
UPLC-MS/MS analysis of AEA, PEA, and OEA was performed on a Sciex
6500 QTRAP system with an IonDrive Turbo V source for
TurbolonSpray® (Sciex, Ontario, Canada) attached to a Shimadzu UPLC
system (Kyoto, Japan) controlled by Analyst software (Sciex, Ontario,
Canada). Chromatographic separation of AEA, PEA, and OEA was
performed on a Discovery® HS C18 Column 15 cm×2.1mm, 3 μm
(Supelco: Bellefonte, PA) kept at 25 °C. The mobile phase consisted of A:
acetonitrile and B: water with 1 g/L ammonium acetate and 0.1%
formic acid. The following gradient was used: 0.0–2.4min at 40% A,
2.5–6.0 min at 40% A, hold for 2.1 min at 40% A, then 8.1–9min 100%
A, hold at 100% A for 3.1min and return to 40% A at 12.1min with a
flow rate was 1.0mL/min. The source temperature was set at 600 °C
and had a curtain gas at a flow rate of 30mL/min. The ionspray voltage
was 5000 V with ion source gases 1 and 2 flow rates of 60 and 50mL/
min, respectively. The mass spectrometer was run in positive ionization
mode for AEA, PEA and OEA. The acquisition mode used was multiple
reaction monitoring (MRM). The following transition ions (m/z) with
their corresponding collection energies (eV) in parentheses were used:
AEA: 348 > 62 (13) and 348 > 91 (60); AEA-d8: 356 > 63 (13);
PEA: 300 > 62 (28) and 300 > 283 (19); PEA-d4: 304 > 62 (28);
OEA: 326 > 62 (30) and 326 > 309 (20); OEA-d4: 330 > 66 (30).
The total run time for the analytical method was 14min. Calibration
curves were analyzed with each analytical batch for each analyte. A
linear regression of the ratio of the peak area counts of analyte and the
corresponding deuterated ISTDs versus concentration was used to
construct the calibration curves. Final AEA, PEA and OEA concentra-
tions were normalized by cell collection numbers. At least three in-
dependent experiments were run for each treatment.
Fig. 1. Presence of CB1R in primary dissociated
PFC neuronal cultures at day in vitro 7–11. (A)
Immunohistochemistry was conducted on PFC neu-
rons (DIV 7–11) to identify cellular distribution of
CB1R. Cells were stained for Map2 (green) and en-
dogenous CB1R (red), and imaged using the Zeiss
LSM 700 confocal microscope. CB1R are localized in
the soma and dendritic processes of PFC neurons,
indicating that the cannabinoid machinery is present
in our PFC primary cell culture model. (B)
Immunohistochemistry was conducted on PFC neu-
ronal cultures to calculate a ratio of glial cells to
neurons. Cells were stained for Map2ab (green) and
GFAP (red), and imaged using the Zeiss Axio
Observer Z.1 microscope. (B') GFAP-positive cells
with astrocyte morphology were present in our PFC
cultures and made up about 11% of the cultured cells.
The percent astroglia composition was not sig-
nificantly altered by Tat 100 nM incubation and/or
time (DIV 7–11). Independent assessment of astro-
glial (B'') and neuronal (B''') populations revealed a
significant reduction in both populations over 4 days
in vitro (DIV 7–11). Further, for Map2ab-positive
neuronal population a significant time by Tat inter-
action was noted that further decreased neuronal cell
count. Statistical significance was assessed by two-
way ANOVAs (at least three independent experi-
ments), *p < 0.05 main effect of time, #p < 0.05
time×Tat interaction. Scale bars= 20 μm.
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2.9. Statistical analyses
Data were analyzed using analyses of variances (ANOVAs) with
Bonferroni's correction as necessary (SPSS Statistics, Version 24, IBM).
For experiments that included various control groups (pretreatment
alone groups, including PF3548, SR1, AM630) only the actual “control”
(no drug) group was integrated in statistical analysis as no significant
differences were noted between any of the control groups. Violations of
compound symmetry in repeated-measures ANOVAs for the within-
subjects factors (i.e., comparing time points) were addressed by using
the Greenhouse-Geisser degrees of freedom correction factor
(Greenhouse and Geisser, 1959). An alpha level of p < 0.05 was con-
sidered significant for all statistical tests. Statistics not shown in the text
were found to be non-significant. Data are expressed as the mean ±
standard error of the mean (SEM). Investigators were blind to the
identity of all experimental conditions during analysis.
3. Results
3.1. Immunocytochemistry
Cell cultures were imaged to visualize cell types and determine the
presence of CB1R (Fig. 1). Differentiated neurons (DIV 7–11) were
treated with antibodies specific to MAP2ab (green), CB1R-NH (red) and
counterstained with Hoechst 33342 (blue; Fig. 1A). Neurons stained
positive for MAP2ab and show CB1R expression localized in the neu-
ronal somata and dendritic processes. No positive CB1R staining was
detected in tissue derived from CB1R knockout mice (data not shown).
Immunocytochemistry indicates that CB1R is present in PFC neuronal
cultures and thus may be sensitive to increases in endocannabinoid
signaling following FAAH enzyme inhibition using PF3845. Using a
primary antibody specific to GFAP (red) glial cells can be detected
alongside neurons (MAP2ab, green; Fig. 1B). Quantification of percent
astrocytes were taken from neuronal cultures at DIV 7 and DIV 11 re-
spective to when calcium experiments were conducted, and when
neuronal survival experiments ended. A small but significant percen-
tage of glia was noted in the cell population of our neuronal cultures
(10.8 ± 0.86; t(65)= 12.5, p < 0.001; Fig. 1B’). A two-way ANOVA
did not reveal any significant main effects for time [F(1, 61)= 3.44,
p=0.068], treatment [F(1, 61)= 2.26, p=0.138], or time× treat-
ment interaction [F(1, 61)= 0.34, p = 0.560], indicating that the
percent ratio of glia to neurons did not significantly change over the
entirety of the experimental time course. When evaluating each cell
population independently, a two-way ANOVA showed a significant
reduction in neuronal and astroglial populations over time (72 h), in-
dicated by a significant main effect for time for both GFAP+ astrocytes
[F(1, 61)= 6.43, p=0.014; Fig. 1B’’] and MAP2ab+ neurons [F(1,
61)= 138.68, p < 0.001; Fig. 1B’’’]. There was also a significant
time× treatment interaction for neurons [F(1, 61)= 6.17, p=0.016;
Fig. 1B’’’], suggesting that Tat treatment further decreases neuron count
over the 72 h time period.
3.2. Calcium imaging
[Ca2+]i levels were assessed over time in PFC neuronal cultures to
evaluate the potential neuroprotective effects of PF3845 after Tat ex-
posure (Fig. 2).
3.2.1. Tat increases [Ca2+]i levels in PFC cultured neurons in a
concentration-dependent manner
Neurons were incubated with fura-2AM to visualize live changes in
[Ca2+]i over a 30min period (Fig. 2A). Application of Tat onto cultured
PFC neurons induced significant changes in [Ca2+]i in a concentration-
dependent manner (Fig. 2B). A two-way ANOVA showed a significant
Fig. 2. Calcium changes in cultured PFC neurons
over 30min. (A) Pseudocolor images of control and
Tat conditions assessing changes in [Ca2+]i levels by
ratiometric imaging of fura-2AM indicated minimal
changes for control (white arrowheads, top row) but
prominent changes for Tat 100 nM over a 30min
time period (white arrowheads, bottom row). (B)
Significant Tat concentration-dependent increases in
[Ca2+]i levels were noted over 30min with Tat
100 nM and 500 nM being significantly different from
control. (C) The significant increase in [Ca2+]i levels
by Tat 100 nM was significantly decreased by PF3845
pretreatment (10, 50, 100 nM) in a concentration-
dependent manner (PF3845 pretreatment 30min
prior Tat application). (D) The protective effect of
PF3845 100 nM pretreatment against Tat-induced
increase in [Ca2+]i levels was blocked by SR1 50 nM
but not AM630 50 nM (CBR pretreatment 30 min
prior PF3845 application). Statistical significance
was assessed by ANOVAs followed by Bonferroni's
post hoc tests; *p < 0.05 vs. control, #p < 0.05 vs.
Tat 100 nM, δp<0.001 vs. Tat 500 nM, ¶p < 0.05
vs. PF3845 100 nM, $p < 0.001 vs. SR1
50 nM + PF3845 100 nM + Tat 100 nM (at least
three independent experiments). SR1: SR141716A.
Scale bars = 20 μm.
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main effect for both, time [F(35, 10255)= 13.2, pGG < 0.001] and
treatment [F(5, 293)= 55.8, p < 0.001], and a significant treat-
ment× time interaction effect [F(175, 10255)= 7.0, pGG < 0.001]. A
one-way ANOVA was conducted on the initial time period where
[Ca2+]i increase (1–5min), and during the latter time period
(20–30min) where [Ca2+]i decreases slightly and plateaus. A sig-
nificant treatment effect was noted for the initial (F(5, 293)= 38.3,
p < 0.001) and the latter neuronal response (F(5, 293)= 33.3,
p < 0.001). During the initial phase, Tat 100 nM and 500 nM condi-
tions significantly increased [Ca2+]i levels compared to control, Tat
5 nM, 10 nM, and 50 nM conditions (p < 0.001). The Tat 500 nM effect
on [Ca2+]i levels was also significantly greater compared to the Tat
100 nM treatment effect (p=0.003). For the latter phase the same
group differences were found as reported for the initial phase.
3.2.2. PF3845 blunts Tat-mediated increases in neuronal [Ca2+]i levels in
a concentration-dependent manner
Pretreating cultured PFC neurons with PF3845 blunts Tat 100 nM-
mediated increases in [Ca2+]i levels in a concentration-dependent
manner (Fig. 2C). A two-way ANOVA revealed a significant main effect
of time [F(35, 9625)= 11.2, pGG < 0.001] and treatment [F(5,
275)= 14.2, p < 0.001], and a significant treatment× time interac-
tion effect [F(175, 9625)= 2.6, pGG < 0.001]. A one-way ANOVA
conducted on the initial [Ca2+]i phase demonstrated a significant
treatment effect [F(5, 269)= 19.7, p < 0.001] with all concentrations
of PF3845 (10, 50, 100 nM) + Tat 100 nM reducing [Ca2+]i levels
compared to the Tat 100 nM condition (p=0.046, p=0.003,
p < 0.001; respectively). Note that only the PF3845 100 nM + Tat
condition was able to maintain [Ca2+]i levels at values that were not
significantly different from control. For the latter phase, a one-way
ANOVA also demonstrated a significant treatment effect [F(5,
268)= 7.8, p < 0.001], with the PF3845 100 nM condition resulting
in significantly reduced [Ca2+]i levels compared to the Tat 100 nM only
condition (p=0.002), and showing no significant difference from
control.
3.2.3. PF3845 blunting effect on [Ca2+]i levels is CB1R, but not CB2R,
dependent
Using selective CB1R and CB2R antagonists (SR1 and AM630, re-
spectively) it was determined that the specificity of PF3845's neuro-
protective effect on Tat-exposed PFC neurons (Fig. 2D). A two-way
ANOVA revealed a significant main effect for time [F(35, 8540)= 9.49,
pGG < 0.001] and treatment [F(4, 244)= 14.00, p < 0.001], and a
significant treatment× time interaction effect [F(140, 8540)= 2.84,
pGG < 0.001]. A one-way ANOVA conducted on the initial [Ca2+]i
phase revealed a significant treatment effect [F(4, 246)= 20.04,
p < 0.001], with SR1 50 nM blocking the protective effect of PF3845
against Tat-induced increase in [Ca2+]i levels (SR1 50 nM + PF3845
100 nM + Tat 100 nM; p < 0.001 vs. control; p = 0.040 vs. AM630
50 nM + PF3845 100 nM + Tat 100 nM). In contrast, the CB2R an-
tagonist AM630 50 nM revealed no significant difference from control
in combination with PF3845 100 nM + Tat 100 nM and showed sig-
nificant lower [Ca2+]i levels from Tat 100 nM (p < 0.001), thus failing
to prevent the protective effects of PF3845 100 nM against Tat-induced
[Ca2+]i level increases. In the latter phase the one-way ANOVA in-
dicated a significant treatment effect [F(4, 246)= 7.65, p < 0.001]
with similar group differences as reported for the initial phase. None of
the various control conditions, including PF3845 100 nM, SR1 50 nM,
and AM630 50 nM, varied significantly from the control group across
any of the presented phases.
3.3. Morphological changes quantified by Imaris analysis
Considering synapto-dendritic injury plays an essential role in the
pathogenesis of HAND we examined Tat and FAAH enzyme inhibitor
PF3845 effects after 24 h on dendritic morphology (length, volume,
process filaments) using Imaris for quantification (Fig. 3). Neurons were
visualized as 3D representations and individual dendritic processes
were analyzed (Fig. 3A). A one-way ANOVA on total dendritic length
(μm) showed a significant treatment effect [F(4, 82)= 10.13,
p < 0.001], with a significant decrease of dendritic length by all Tat
treatment conditions (Fig. 3B). A one-way ANOVA on total dendritic
volume (μm3) revealed a significant treatment effect [F(4, 82)= 18.96,
p < 0.001] with a significant downregulation of dendritic volume by
Tat 100 nM (p < 0.001, Fig. 3C). Importantly, pretreating Tat-exposed
neurons with PF3845 100 nM significantly increased volume of den-
drites, indicating a protective effect of PF3845 against Tat-induced
downregulation of dendritic volume (p < 0.001). Interestingly, pre-
treating PF3845 100 nM + Tat 100 nM-exposed neurons with AM630
but not SR1 blocked the protective effects of PF3845 100 nM against
Tat toxicity, implying an underlying CB2R-related mechanism for sy-
napto-dendritic injury after 24 h Tat treatment, specifically when
looking at total dendritic volume. Lastly, a one-way ANOVA on the total
number of dendritic filaments revealed no significant treatment effect
[F(4, 88)= 0.48, p=0.748], indicating that the dendritic filament
number did not change significantly for any treatment condition
Fig. 3. Morphological changes on dendrites of
PFC neuronal cultures. (A) Three-dimensional re-
construction of PFC neuronal dendrites at DIV 8 (B)
Total dendritic length (μm) is significantly decreased
by Tat 100 nM after 24 h. No protective effect was
noted when pretreating Tat-exposed neurons with the
FAAH enzyme inhibitor PF3845 100 nM. (C) In con-
trast, the significant reduction of total dendritic vo-
lume (μm3) by Tat 100 nM was prevented with pre-
treatment of PF3845 100 nM. Interestingly, whereas
SR1 50 nM was not able to block the protective ef-
fects of PF3845 100 nM, the CB2R antagonist AM630
50 nM reduced dendritic volume comparably to the
Tat 100 nM treatment condition. (D) The total
number of process filaments were not significantly
different between conditions. Statistical significance
was assessed by ANOVAs followed by Bonferroni's
post hoc tests; *p < 0.01 vs. control, #p < 0.001 vs.
Tat 100 nM, $p < 0.05 vs. AM630 50 nM + PF3845
100 nM + Tat 100 nM (at least three independent
experiments). SR1: SR141716A. Scale bars = 10 μm.
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(Fig. 3D). None of the various control conditions, including PF3845
100 nM, SR1 50 nM, and AM630 50 nM, varied significantly from the
control group.
3.4. Neuronal survival
Neuronal survival after PF3845 ± Tat exposure over a 72 h time
period was assessed to evaluate the potential protective effects of
PF3845 against neuronal death (Fig. 4).
3.4.1. Tat potentiates neuronal death in a concentration-dependent manner
Neurons were visualized using phase-contrast microscopy (Fig. 4A).
Challenging neurons with Tat for 72 h decreased neuronal viability in a
Tat dose-dependent fashion (Fig. 4B). A two-way ANOVA on neuronal
survival demonstrated a significant main effect of time [F(18,
1224)= 140.8, pGG < 0.001] and a significant treatment× time in-
teraction [F(54, 1224)= 3.4, pGG < 0.001]. A one-way ANOVA con-
ducted on the last 72nd h time point indicated a significant treatment
effect [F(3, 68)= 4.0, p=0.011], with Tat 100 nM condition sig-
nificantly reducing neuronal survival compared to control (p < 0.016).
3.4.2. PF3845 increases neuronal survival after Tat exposure in a
concentration-dependent manner
Pretreating neurons with different concentrations of PF3845 pro-
duce neuroprotective effects against Tat-exposure (Fig. 4C). For the
two-way ANOVA a significant effect was noted for time [F(18,
1224)= 153.3, pGG < 0.001] and treatment× time interaction [F(54,
1224)= 4.2, pGG < 0.001]. A one-way ANOVA on the 72nd h time
point revealed a significant treatment effect [F(3, 68)= 4.0,
p = 0.012], with Tat 100 nM and PF3845 50 nM + Tat significantly
reducing neuronal survival compared to control (p=0.039 and
p = 0.033, respectively). In contrast, the higher PF3945 100 nM con-
centration protected against neuronal death, with PF3845
100 nM + Tat showing no significant difference from control.
3.4.3. PF3845 protective effects on neuronal death are CB2R dependent
Using selective CB1R and CB2R antagonists (SR1 and AM630, re-
spectively) it was determined which of these receptors mediated
PF3845's neuroprotective effect against Tat-mediated neuronal death
(Fig. 4D). A two-way ANOVA showed a significant effect for time [F(18,
3366)= 338.40, pGG < 0.001] and treatment× time interaction [F
(72, 3366)= 4.73, pGG < 0.001]. A one-way ANOVA on the 72nd h
time point revealed a significant treatment effect [F(4, 187)= 6.32,
Fig. 4. Changes in neuronal survival in cultured
PFC neurons over 72 h. (A) Phase images of PFC
neuronal cultures of control and Tat conditions asses-
sing neuronal survival in a time-lapse study over a 72 h
time period. A single neuron followed for the control
condition shows neuronal survival over 72 h (white
arrowheads, top row), whereas a single neuron fol-
lowed after exposure to Tat 100 nM died at approxi-
mately 36 h (white arrowheads, bottom row) although
other adjacent neurons remain alive and occasionally
exhibit movement during this time period (white
arrow, bottom row). (B) Treatment of Tat 100 nM for
72 h significantly reduced the survival of PFC neurons
in a concentration-dependent manner, with Tat
100 nM being significantly different from control. (C)
The significant decrease of neuronal survival by Tat
100 nMwas significantly decreased by PF3845 100 nM
pretreatment (30 min prior Tat application). (D) The
protective effect of PF3845 100 nM pretreatment
against Tat-induced increase in neuronal death was
blocked by AM630 50 nM but not SR1 50 nM (CBR
pretreatment 30 min prior PF3845 application). (E)
Immunohistochemistry was conducted on PFC neu-
ronal cultures to calculate the proportion of activated
caspase-3 (red) in NeuN-positive neurons (green)
(white arrowhead, co-staining). Cells were imaged
using the Zeiss Axio Observer Z.1 microscope. (F) A
significant increase in caspase-3 positive neurons was
noted for Tat 100 nM and AM630 50 nM + PF3845
100 nM + Tat 100 nM, suggesting that PF3845 pro-
tects neurons against Tat-induced neuronal injury and/
or death through CB2R related signaling. Statistical
significance was assessed by ANOVAs followed by
Bonferroni's post hoc tests; *p < 0.05 vs. control,
#p < 0.05 vs. Tat 100 nM, δp<0.05 vs. PF3845
50 nM + Tat 100 nM, $p < 0.05 vs. AM630
50 nM+ PF3845 100 nM+ Tat 100 nM (at least three
independent experiments). SR1: SR141716A, Casp3:
active caspase-3. Scale bars = 20 μm.
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p < 0.001], with Tat and Tat + AM630 significantly reducing neu-
ronal survival from control. None of the various control conditions,
including PF3845 100 nM, SR1 50 nM, and AM630 50 nM, significantly
affected cell death compared to the control group.
3.4.4. PF3845 decreases activated caspase-3 positive neurons following Tat
exposure
Using antibodies against activated caspase-3 and NeuN, it was
possible to quantify the number of neurons expressing activated cas-
pase-3 after 72 h of Tat exposure (Fig. 4E). A one-way ANOVA de-
monstrated a significant main effect for treatment [F(4, 45)= 10.79,
p < 0.001] with Tat 100 nM and AM630 + PF + Tat significantly
increasing the number of caspase-3 positive neurons (Fig. 4F). This
provides further evidence that PF3845 protects against Tat-mediated
apoptotic cell death via a CB2R-dependent mechanism. None of the
various control conditions, including PF3845 100 nM, SR1 50 nM, and
AM630 50 nM, varied significantly from the control group.
3.5. Mass spectrometry
UPLC-MS/MS was used to determine the expression of AEA and
other predominant substrates of FAAH in the presence of PF3845
100 nM ± Tat 100 nM (Fig. 5). Neurons exposed to PF3845 ± Tat
were collected after 30min for analysis of AEA, PEA, and OEA con-
centrations. 2-AG levels were not assessed as past literature demon-
strated that PF3845 administration does not significantly alter 2-AG
concentration in brain tissue (Ahn et al., 2009; Booker et al., 2012). A
two-way ANOVA found a significant main effect of PF3845 for both
AEA [F(1,12)= 6.16, p=0.029] and PEA [F(1,11)= 6.77, p=0.025],
but not OEA [F(1,12)= 2.11, p=0.172]. No significant main effect for
Tat treatment was found for either AEA [F(1,12)= 1.26, p=0.284],
PEA [F(1,11)= 1.91, p=0.195], or OEA [F(1,12)= 0.11, p=0.748].
Additionally no significant PF3845 x Tat interactions were noted, AEA
[F(1,12)= 0.03, p=0.861], PEA [F(1,11)= 0.60, p=0.455], and
OEA [F(1,12)= 3.14, p=0.102]. As hypothesized, PF3845 100 nM
significantly increased concentrations of some lipids targeted by FAAH,
represented by an approximate 2-fold increase in AEA concentration
and an approximate 5-fold increase in PEA concentration in the control
vs. PF3845 ± Tat conditions. No significant effect main effect was
found for any OEA condition.
4. Discussion
Our results demonstrate that a highly selective FAAH inhibitor,
PF3845, inhibits increases in neuronal [Ca2+]i levels, promotes cell
survival, and prevents loss of normal dendrite morphology in Tat
treated murine PFC neuronal cultures. These effects were mediated via
a CB1R and/or CB2R and likely induced by increased endocannabinoid
signaling following FAAH inhibition.
The [Ca2+]i imaging results show that neurons exposed to Tat
100 nM significantly increase intracellular calcium in a stereotypical
fashion (initial and latter phases of [Ca2+]i increase) similar to what
has been described earlier (Brailoiu et al., 2008). This increase in
calcium is a combination of Ca2+ influx as a consequence of NMDA
receptor activation (Haughey et al., 2001; Perez et al., 2001; Longordo
et al., 2006; Fitting et al., 2014) and release of Ca2+ from intracellular
stores mediated via inositol 1,4,5-trisphosphate (IP3) and/or ryanodine
receptor pathways (Haughey et al., 1999; Fitting et al., 2014). The Tat-
mediated [Ca2+]i effect shows differential sensitivity to various con-
centrations of PF3845. While PF3845 100 nM significantly blunts
[Ca2+]i levels across the entire time period, lower concentrations (i.e.
10 nM and 50 nM) only significantly blunt the initial phase of the Tat
effect. Considering that the initial spike in Tat-mediated [Ca2+]i pri-
marily results from Ca2+ release from intracellular stores (Chami et al.,
2006), the presented data suggest that Tat's influence on IP3/ryanodine
receptor pathways is more sensitive to PF3845 treatment than NMDAR
activity. The role of CB1R in protecting neurons from NMDA-induced
cytotoxicity has been shown to be IP3 receptor-dependent (Liu et al.,
2009), and intracellular CB1R activity has been linked with accessing
lysosome and endoplasmic reticulum calcium stores (Brailoiu et al.,
2011) suggesting that CB1R activation may disrupt the ability of Tat to
exert its effects on [Ca2+]i. CB1R has also been found to form hetero-
dimers with NMDARs (Sanchez-Blazquez et al., 2014) and disrupting
the formation of this complex has been shown to block the ability of
CB1R to attenuate damage from excitotoxic insults (Vicente-Sanchez
et al., 2013).
When examining the neurotoxic effects of Tat it is also important to
consider the role of disruptions in healthy dopamine signaling. A po-
tential alternative/complementary explanation for the effects that we
have observed stems from Tat's ability to bind and inhibit dopamine
transporter activity (DAT) (Quizon et al., 2016) leading to increased
dopamine levels which could contribute to neurotoxic conditions. In-
terestingly, human DAT activity in HIV-1 patients negatively correlates
with HAND symptom severity (Wang et al., 2004; Chang et al., 2008)
suggesting it plays an important role in the development of HAND
pathology. While outside the scope of the experiments presented here,
exploring the effect of Tat on the dopaminergic system and how it in-
teracts with cannabinoid signaling in our culture model could offer
additional insights into developing effective treatments for HAND pa-
tients.
While CB1R activity played a significant role in reducing Tat-
mediated neurotoxicity, CB2R activity also played an essential role in
neuronal survival and protecting against Tat-induced decreases in
dendritic volume. Using SR1 and AM630 showed that PF3845 amelio-
rated Tat-mediated neuronal death and loss of dendritic structure
through CB2R signaling, but independently of CB1R signaling. This
finding suggests that the 11% astroglial component of our cultures
(Fig. 1B) likely plays a role in these protective effects, as glia such as
murine astrocytes are known to express CB2R (Stella, 2010) and con-
tribute to ion buffering, regulation of neurotransmitters, and supporting
neuronal growth (Newman, 2003; Lian and Stringer, 2004; Rossi,
2015). A similarly small population of glia have been observed in
earlier reports using this culture model (Fitting et al., 2014). Morphine
was shown to potentiate Tat-mediated neurotoxicity via μ-opioid re-
ceptors in striatal neuronal cultures but based on earlier findings these
effects were found to be astrocyte specific (Zou et al., 2011), suggesting
Fig. 5. PF3845 mediated changes in en-
docannabinoid concentration in PFC neuron cul-
tures. Concentrations of AEA, PEA, and OEA were
assessed using UPLC-MS/MS after 30 min of PF3845
100 nM ± Tat 100 nM exposure. Lipid concentra-
tions were normalized to cell count for each in-
dependent experiment. A significant main effect of
PF3845 treatment was detected for AEA and PEA. No
significant differences were noted for OEA. Statistical
significance was assessed by two-way ANOVAs;
*p < 0.05 main effect of PF3845. Each condition
represents at least three independent experiments.
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that even a small population of glial cells can play a significant role in
attenuating Tat-mediated neurotoxicity. Glial cells expressing CB2R's
have been demonstrated to be viable targets for protecting neurons
from HIV-1 associated neurodegeneration as shown in several models of
HAND (Price et al., 2009; Kim et al., 2011; Hu et al., 2013), which
indicates the importance of targeting neuroinflammatory signaling in
this condition. Alternatively, evidence exists that suggests that CB2R is
sparsely expressed in neuronal populations, some which have been
found in the ventral tegmental area (VTA) and hippocampus (Zhang
et al., 2017; Li and Kim, 2017). Therefore, it would be necessary for
further study to detect the presence or lack thereof CB2R in murine PFC
and ascertain its potential role in influencing Tat-mediated neuronal
damage.
Disruption of synaptic structures is a major component of HAND
and the prevention and/or reversibility of this damage is of major in-
terest to the field (Ellis et al., 2007). In the present study neurons were
exposed to PF3845 ± Tat and reconstructed to characterize the
changes in neuronal dendritic morphology. Decreases in MAP2ab
staining in human frontal cortex has been associated with higher viral
load and decreased neurocognitive function in HIV-1 infected in-
dividuals (Levine et al., 2016), and direct treatment of cultured hip-
pocampal neurons with Tat has been shown to decrease MAP2ab ex-
pression (Butler et al., 2011). The analysis of the results revealed an
interesting interaction between Tat and PF3845 where PF3845 failed to
effect Tat-mediated loss of dendritic length but did preserve overall
dendritic volume. Because there was not a significant alteration in the
total number of process filaments per neuron in each condition this
suggests that PF3845 increases the cross-sectional area of the MAP2ab
expressed within the individual dendritic structures. This could be in-
dicative of dendritic swelling, which has been reported to result from
Tat infliction (Xu et al., 2017), and is known to precede further de-
generation in multiple models of neurodegenerative conditions
(Jaworski et al., 2011; Chen et al., 2017). The differences between the
Tat and PF3845 + Tat conditions suggests that PF3845 treatment may
slow or halt the progression of synaptodendritic damage mediated by
Tat. Our lab has shown that Tat attenuates GABAergic function in our
current culture model, which can be blocked by application of CB1R
agonists (Xu et al., 2016). This demonstrates that while our cultures are
relatively immature at DIV 7, functional consequences of Tat infliction
can be quantified. In the future we plan to use older cultures to allow
for further observation of functional changes in neuronal morphology
(e.g. dendritic spine morphology/density) and the resulting data will be
essential in ascertaining PF3845's ability in preserving neuronal func-
tionality and/or reversing damage following Tat infliction.
The neuroprotective effects of PF3845 in our Tat-exposed PFC
neuronal cultures may be due to the elevation of AEA and/or PEA
concentrations. Increases in PEA alongside AEA were of great interest
because this fatty acid amide has been shown to produce anti-in-
flammatory and neuroprotective activity through the peroxisome pro-
liferator-activated receptor family (Landreth, 2007; Bright et al., 2008;
Scuderi et al., 2012; Paterniti et al., 2014). A previous study using
murine brain tissue demonstrated increased expression of endogenous
N-acylethanolamide molecules, including AEA and PEA following ad-
ministration of PF3845 (Wiebelhaus et al., 2015).
Overall these findings indicate that inhibiting FAAH activity can
protect neurons against Tat infliction. This raises the question if the
removal of HIV-1 related stressors on neurons may elicit dendritic re-
generation and restoration of cognitive function. Therefore, while
PF3845 was effective in attenuating Tat-mediated neurotoxicity, it will
be important to further explore whether its application can reverse pre-
existing Tat-induced neuronal injuries.
5. Conclusion
The presented data show the capacity of the HIV-1 Tat protein to
destabilize neuronal calcium equilibrium, increase neuronal death, and
mediate dendritic degeneration while application of the highly selective
and potent FAAH inhibitor, PF3845, is able to attenuate these effects.
The results of the calcium experiments supported the hypothesis that
enhancing AEA concentration using PF3845 will produce neuropro-
tective effects via neuronal CB1R. The findings that the CB2R played a
key role in attenuating Tat -mediated increases in neuronal death and
dendritic degeneration over 72 and 24 h, respectively, suggest that
CB2Rs likely play a pertinent role in Tat-mediated neurodegeneration
and can be targeted for therapeutic benefit by drugs such as PF3845. In
addition, it will be important to evaluate the potential role of specific
CB2R ligands as therapeutic drugs in treatment of HAND. Future ex-
periments will be necessary to further understand the interaction be-
tween Tat and CNS resident neurons and glial cells in the pathogenesis
of HAND and how pharmaceutical agents targeting the endogenous
cannabinoid system can potentially block or reverse these neurode-
generative conditions.
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